Document Detail

Cotinine: A Potential New Therapeutic Agent against Alzheimer's disease.
MedLine Citation:
PMID:  22530628     Owner:  NLM     Status:  Publisher    
Tobacco smoking has been correlated with a lower incidence of Alzheimer's disease (AD). This negative correlation has been attributed to nicotine's properties. However, the undesired side-effects of nicotine and the absence of clear evidence of positive effects of this drug on the cognitive abilities of AD patients have decreased the enthusiasm for its therapeutic use. In this review, we discuss evidence showing that cotinine, the main metabolite of nicotine, has many of the beneficial effects but none of the negative side-effects of its precursor. Cotinine has been shown to be neuroprotective, to improve memory in primates as well as to prevent memory loss, and to lower amyloid-beta (Aβ)) burden in AD mice. In AD, cotinine's positive effect on memory is associated with the inhibition of Aβ aggregation, the stimulation of pro-survival factors such as Akt, and the inhibition of pro-apoptotic factors such as glycogen synthase kinase 3 beta (GSK3β). Because stimulation of the α7 nicotinic acetylcholine receptors (α7nAChRs) positively modulates these factors and memory, the involvement of these receptors in cotinine's effects are discussed. Because of its beneficial effects on brain function, good safety profile, and nonaddictive properties, cotinine may represent a new therapeutic agent against AD.
Valentina Echeverria; Ross Zeitlin
Related Documents :
7844508 - Responses to quantity: perceptual versus cognitive mechanisms in chimpanzees (pan trogl...
24993058 - Neurod1 modulates opioid antinociceptive tolerance via two distinct mechanisms.
20718558 - Great apes select tools on the basis of their rigidity.
15677098 - Ergonomic research in the german travelling mail services part 2: results of ergonomic ...
16310318 - The role of androgens in cognition and brain aging in men.
11641888 - Altering the balance of recollection and familiarity influences the revelation effect.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-4-25
Journal Detail:
Title:  CNS neuroscience & therapeutics     Volume:  -     ISSN:  1755-5949     ISO Abbreviation:  -     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-4-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101473265     Medline TA:  CNS Neurosci Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2012 Blackwell Publishing Ltd.
Bay Pines VA Healthcare System, Bay Pines, Tampa, FL, USA Department of Molecular Medicine, University of South Florida, Tampa, FL, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pain management in patients with haemophilia: a European survey.
Next Document:  The effect of maternal class III obesity on neonatal outcomes: a retrospective matched cohort study.